RiboX Therapeutics secures FDA IND clearance for RXIM002, the world's first circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias, enabling Phase 1 trial initiation
Executive summary: RiboX Therapeutics received FDA Investigational New Drug (IND) clearance for RXIM002, the first circular RNA-based in vivo CAR-T therapy designed to treat autoimmune cytopenias, enabling the start of a Phase 1 clinical trial. This is the world’s first FDA-authorized circular RNA-based in vivo CAR therapy, offering a potentially more precise and safer alternative to conventional immunosuppressants for autoimmune diseases by enabling targeted, transient CAR-T expression directly in the body.
Who is involved: RiboX Therapeutics (sponsor), U.S. Food and Drug Administration (regulator), and clinical trial investigators (to be engaged in Phase 1).
Likely next: Initiation of Phase 1 clinical trial dosing, followed by safety and pharmacokinetic readouts; potential future IND-enabling studies for broader autoimmune or oncology indications if Phase 1 succeeds.
RiboX Therapeutics announced FDA IND clearance for RXIM002, a novel therapeutic combining circular RNA delivery via lipid nanoparticles with in vivo CAR-T cell generation to treat autoimmune cytopenias. This milestone represents the first regulatory authorization for a circular RNA-based in vivo CAR therapy, addressing a significant unmet need in autoimmune disorders where current treatments are often broad immunosuppressants with substantial side effects. The clearance allows RiboX to begin Phase 1 clinical trials to evaluate safety, tolerability, and preliminary efficacy of this targeted approach. The development underscores growing innovation in nucleic acid-based immunotherapies and positions RiboX at the forefront of next-generation cell therapy engineering.
Timeline
- — RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias (PR Newswire)
- — Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy (PR Newswire)
Analysis — what this means
Likely next events
- RiboX Therapeutics to announce Phase 1 trial site activation and first patient dosing for RXIM002 by Q4 2026
- Interim safety and pharmacokinetics data from RXIM002 Phase 1 trial expected in H1 2027
- FDA may request additional preclinical biodistribution or shedding data prior to Phase 2 based on novel mechanism
Sectors affected
- Autoimmune disease therapeutics
- Circular RNA drug delivery
- In vivo cell therapy
- Lipid nanoparticle (LNP) therapeutics
Regulatory implications
- FDA sets precedent for IND clearance of circular RNA-based in vivo immunotherapies, potentially streamlining future submissions
- LNP delivery systems for nucleic acid therapeutics face heightened scrutiny on off-target expression and immune activation
- Manufacturing and potency assays for circular RNA may require new guidance as first-in-class modality advances
Historical parallels
- First FDA approval of a CAR-T therapy (tisagenlecleucel, 2017) for rel/ref B-ALL
- First siRNA drug approval (patisiran, 2018) establishing LNP delivery for nucleic acid therapeutics
- First mRNA vaccine EUA (BNT162b2, 2020) demonstrating rapid clinical translation of nucleic acid platforms
Key entities
Sources
Open the full interactive case file on Beyond →